Cancer Screening Market 2022-2028

Description

List of Tables

Title:Global Cancer Screening Market Size, Share, and Trends Analysis Report, by Screening Type (Diagnostic Imaging Tests, Biopsy & Cytology Tests, Tumor Biomarkers, and Others), and By Application (Breast Cancer, Lung Cancer, Cervical Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Ovarian Cancer, and Others), Forecast Period (2022-2028).

The global cancer screening market is anticipated to grow at a CAGR of 10.0% during the forecast period. The major factors driving the growth of the market include the rising prevalence of cancer coupled with the increasing demand for internal radiation therapy. According to the International Agency for Research on Cancer (IARC), in 2018 there were 17.0 million new cancer cases reported and 9.5 million cancer mortalities registered across the globe. By 2040, the global burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer mortalities every year, majorly due to an unhealthy lifestyle.

The global cancer screening market is segmented based on the screening type and application. Based on the screening type, the market is segmented into diagnostic imaging tests, biopsy & cytology tests, tumor biomarkers, and others. Based on the application, the market is sub-segmented into breast cancer, lung cancer, cervical cancer, kidney cancer, liver cancer, pancreatic cancer, ovarian cancer, and others.

Geographically, the global cancer screening market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Europe holds a considerable share in the global cancer screening market. The factors driving the European market growth include the increasing number of cancer patients, reduction in the cost of radiotherapy, and rising government and non-government investments in R&D of cancer treatment. According to the World Health Organization (WHO), with 4.4 million new cases and 1.9 million fatalities in 2020, cancer represents the second major cause of fatality and morbidity in Europe. In Europe, tobacco consumption and excessive alcohol consumption cause about 40% of the total cancer burden.

The major companies serving the global cancer screening market include Abbott Laboratories Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GE Healthcare, Hologic Inc., Illumina Inc., Bio-Rad Laboratories Inc., Agilent Technologies Inc., and Cancer Diagnostic Inc., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2021, Hologic, Inc. acquired Biotheranostics for its product portfolio of breast and metastatic cancer testing for $230 million and SOMATEX for $64 million.

Research Methodology

The market study of the global cancer screening market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.

Whitepapers, research papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Cancer Screening Market Research and Analysis by Screening Type.
Global Cancer Screening Market Research and Analysis by Application.

The Report Covers:

Comprehensive research methodology of the global cancer screening market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global cancer screening market.
Insights about market determinants that are stimulating the global cancer screening market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2026702

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Cancer Screening Market
Recovery Scenario of Global Cancer Screening Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. Abbott Laboratories Inc.
  - 3.1.1.1. Overview
  - 3.1.1.2. Financial Analysis
  - 3.1.1.3. SWOT Analysis
  - 3.1.1.4. Recent Developments
- 3.1.2. Agilent Technologies Inc.
  - 3.1.2.1. Overview
  - 3.1.2.2. Financial Analysis
  - 3.1.2.3. SWOT Analysis
  - 3.1.2.4. Recent Developments
- 3.1.3. F. Hoffmann-La Roche Ltd.
  - 3.1.3.1. Overview
  - 3.1.3.2. Financial Analysis
  - 3.1.3.3. SWOT Analysis
  - 3.1.3.4. Recent Developments
- 3.1.4. GE Healthcare
  - 3.1.4.1. Overview
  - 3.1.4.2. Financial Analysis
  - 3.1.4.3. SWOT Analysis
  - 3.1.4.4. Recent Developments
- 3.1.5. Thermo Fisher Scientific Inc.
  - 3.1.5.1. Overview
  - 3.1.5.2. Financial Analysis
  - 3.1.5.3. SWOT Analysis
  - 3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

4.1. Global Cancer Screening Market by Screening Type
- 4.1.1. Diagnostic Imaging Tests
- 4.1.2. Biopsy & Cytology Tests
- 4.1.3. Tumor Biomarkers
- 4.1.4. Others
4.2. Global Cancer Screening Market by Application
- 4.2.1. Breast Cancer
- 4.2.2. Lung Cancer
- 4.2.3. Cervical Cancer
- 4.2.4. Kidney Cancer
- 4.2.5. Liver Cancer
- 4.2.6. Pancreatic Cancer
- 4.2.7. Ovarian Cancer
- 4.2.8. Others

5. Regional Analysis

5.1. North America
- 5.1.1. US
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Becton, Dickinson, and Co.
6.2. Bio-Rad Laboratories Inc.
6.3. Cancer Diagnostic Inc.
6.4. DiaSorin S.p.A.
6.5. Epigenomics AG
6.6. Hologic Inc.
6.7. Illumina Inc.
6.8. MedGenome Labs Ltd.
6.9. Positive Biosciences Ltd.
6.10. QIAGEN GmbH
6.11. Siemens Healthineers AG
6.12. Techlab, Inc.
6.13. VolitionRX Ltd.
6.14. 20/20 GeneSystems